Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Adipokines and the Risk of Reflux Esophagitis

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified March 2012 by Donghee Kim, Seoul National University Hospital.
Recruitment status was:  Not yet recruiting
Information provided by (Responsible Party):
Donghee Kim, Seoul National University Hospital Identifier:
First received: March 20, 2012
Last updated: March 21, 2012
Last verified: March 2012
We aimed to risk faoctors for GERD and association between visceral obesity, plasma adipoline(leptin, adiponectin, IL-6, TNF-α)and development of reflux esophagitis in healthy Koreans.

Visceral Obesity
Reflux Esophagitis

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Prospective
Official Title: Adipokines and the Risk of Reflux Esophagitis : Prospective Case-control Study

Resource links provided by NLM:

Further study details as provided by Donghee Kim, Seoul National University Hospital:

Primary Outcome Measures:
  • Difference in serum adipokine levels between case and control groups [ Time Frame: 2 month lager (after sampling) ]

Biospecimen Retention:   Samples Without DNA

Estimated Enrollment: 600
Study Start Date: June 2012
Estimated Primary Completion Date: June 2013 (Final data collection date for primary outcome measure)
Reflux esophagitis
those with endoscopically proven reflux esophagitis
those with normal GFS finding (without definite mucosal break at Z-line)


Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
healthy adults who visit healthcare system for routine checkup

Inclusion Criteria:

  • endoscopically proven reflux esophagitis

Exclusion Criteria:

  • those with esophageal hiatal hernia, current PPI medication, upper GI operation history
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01560598

Contact: Kyung-Sang Yu, Professor +82-2-2072-1920
Contact: Jeong-Hwa Hong, IRB analyst +82-2-740-8096

Korea, Republic of
Seoul National University Hospital Healthcare System Gangnam Center Not yet recruiting
Seoul, Korea, Republic of
Contact: Su Jin Chung, MD    +82-10-8424-8471   
Principal Investigator: Donghee Kim, MD         
Sponsors and Collaborators
Seoul National University Hospital
  More Information

Responsible Party: Donghee Kim, Clinical Assistant Professor, Seoul National University Hospital Identifier: NCT01560598     History of Changes
Other Study ID Numbers: gerdadipokine
Study First Received: March 20, 2012
Last Updated: March 21, 2012

Keywords provided by Donghee Kim, Seoul National University Hospital:
reflux esophagitis
endoscopically proven

Additional relevant MeSH terms:
Gastroesophageal Reflux
Esophagitis, Peptic
Obesity, Abdominal
Esophageal Motility Disorders
Deglutition Disorders
Esophageal Diseases
Gastrointestinal Diseases
Digestive System Diseases
Peptic Ulcer
Duodenal Diseases
Intestinal Diseases
Stomach Diseases
Nutrition Disorders processed this record on May 25, 2017